INVESTORS & MEDIA
Corporate Governance
Corporate Governance
| Date | Name | Title | Type | Shares Traded | Price |
|---|---|---|---|---|---|
| Jun 14, 2005 |
Director
Trans History: 677
|
Director | Other acquisition or disposition (describe transaction) | 182,171 | -- |
| Jun 14, 2005 |
Director
Trans History: 677
|
Director | Other acquisition or disposition (describe transaction) | 182,171 | -- |
| Aug 03, 2017 |
Director, President and CSO
Trans History: 576
|
Director, President and CSO | Bona fide gift | 176,223 | -- |
| Aug 03, 2017 |
Director, President and CSO
Trans History: 576
|
Director, President and CSO | Bona fide gift | 176,223 | -- |
| Jul 21, 2017 |
Director, President and CSO
Trans History: 576
|
Director, President and CSO | Bona fide gift | 176,223 | -- |
| Jul 21, 2017 |
Director, President and CSO
Trans History: 576
|
Director, President and CSO | Bona fide gift | 176,223 | -- |
| Sep 10, 2019 |
Ten Percent Owner
Trans History: 555
|
Ten Percent Owner | Open market or private sale of non-derivative or derivative security | 172,904 | $281.15 |
| Dec 16, 2015 |
Director, President & CEO
Trans History: 361
|
Director, President & CEO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 172,723 | -- |
| Dec 16, 2014 |
Director, President Regeneron Laboratori
Trans History: 576
|
Director, President Regeneron Laboratori | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 172,723 | -- |
| Dec 16, 2011 |
Director, President & CEO
Trans History: 361
|
Director, President & CEO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 160,000 | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.